GlassScriptPhysician profile
Lian Jie Li
NPI 1649259383
$7,016.97
in general payments reported to CMS, 2019-2025
29 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $569 · 2021: $1,241 · 2022: $1,221 · 2023: $1,608 · 2024: $903 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,144 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,143.91 |
| Education | $231.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,047.36 | 2019-2025 | |
| Ucb, INC. | $919.55 | 2020-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $858.21 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Abbvie INC. | $857.16 | 2019-2025 | |
| Janssen Biotech, INC. | $645.56 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $334.22 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $322.69 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $311.90 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $269.16 | 2020-2025 | Otezla, Otezla |
| Helsinn Therapeutics (U.S.), INC. | $216.42 | 2019-2025 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.08 | 2022-2025 | Spevigo |
| Genzyme Corporation | $140.58 | 2021-2025 | |
| Incyte Corporation | $135.86 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $128.30 | 2023-2024 | Zoryve |
| Novo Nordisk INC | $117.19 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.56 | 2021-2023 | |
| Leo Pharma INC. | $74.87 | 2019-2025 | Anzupgo |
| Kyowa Kirin, INC. | $60.55 | 2022-2024 | Poteligeo |
| Biofrontera INC. | $53.52 | 2021 | |
| Galderma Laboratories, L.P. | $49.71 | 2025 | Nemluvio |
| Genentech USA, INC. | $43.04 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.80 | 2019 | |
| Vyne Pharmaceuticals INC. | $25.99 | 2020 | |
| Stemline Therapeutics INC. | $21.47 | 2019 | |
| Convatec INC. | $19.60 | 2024 | |
| Misonix INC | $19.41 | 2021 | |
| Celgene Corporation | $17.65 | 2024 | Sotyktu |
| Journey Medical Corporation | $8.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lian Jie Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.